Neural Therapeutics Inc. is an ethnobotanical drug discovery company dedicated to developing therapeutic drugs targeting mental illnesses, particularly those related to substance use disorders such as alcohol and opioid dependence. The company specializes in leveraging plant-based active substances, with a focus on psychoactive plants like the San Pedro cactus, which contains mescaline. Neural Therapeutics employs an innovative approach, including the strategic use of sub-hallucinogenic doses of mescaline extracts, aiming to create safe and scalable therapies for conditions like depression, anxiety, and addiction. Beyond pharmaceuticals, Neural Therapeutics also explores nutraceutical applications from non-psychoactive compounds found in these plants. The company is expanding its commercial footprint through a strategic partnership and significant equity stake in CWE European Holdings Inc., a leading German hemp- and CBD-based retail platform operating under the Hanf.com brand, which enhances Neural's presence in the growing European natural products market. Based in Toronto, Neural Therapeutics integrates traditional indigenous knowledge with modern science to advance the development of novel mental health treatments and wellness products.